AstraZeneca (AZN) reported second-quarter earnings of $0.83 per share, beating consensus forecast by 7 cents. The company reported revenue of $5.6 billion, down 11.3% on a year-over-year basis. Revenue beat consensus forecast by $40 million.

United Therapeutics (UTHR) reported second-quarter earnings of $4.55 per share, beating consensus forecast by $1.33. The company's revenue for the quarter was $412.6 million, up 18.9% on a year-over-year basis. Revenue beat expectations by $17.45 million.

Acorda Therapeutics (ACOR) reported earnings of $0.07 per share in its second quarter, missing consensus forecast by 13 cents. The company's revenue for the quarter was $127.46 million, up 12.1% on a year-over-year basis. Revenue missed consensus forecast by $0.98 million.

Harvard Biosciences (HBIO) reported earnings of $0.03 per share in its second quarter, which was in-line with the consensus forecast. The company's revenue for the quarter was $26.14 million, down 9.2% on a year-over-year basis. Revenue missed consensus forecast by $0.5 million.

Novocure (NVCR) reported a loss of $0.48 per share in its second quarter. The company's revenue for the quarter was $17.92 million, up 174% on a year-over-year basis.

Alexion Pharmaceuticals (ALXN) reported earnings of $1.13 per share in its second quarter, missing consensus forecast by 4 cents. The company's revenue for the quarter was $753.12 million, up 18.4% on a year-over-year basis. Revenue beat consensus forecast by $9.1 million.